JP2014526254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526254A5 JP2014526254A5 JP2014529994A JP2014529994A JP2014526254A5 JP 2014526254 A5 JP2014526254 A5 JP 2014526254A5 JP 2014529994 A JP2014529994 A JP 2014529994A JP 2014529994 A JP2014529994 A JP 2014529994A JP 2014526254 A5 JP2014526254 A5 JP 2014526254A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- glp
- xten
- fusion protein
- nmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 69
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 69
- 102000037865 fusion proteins Human genes 0.000 claims description 54
- 108020001507 fusion proteins Proteins 0.000 claims description 54
- 230000000968 intestinal effect Effects 0.000 claims description 41
- 230000001965 increasing effect Effects 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 230000006378 damage Effects 0.000 claims description 24
- 230000003247 decreasing effect Effects 0.000 claims description 24
- 208000004232 Enteritis Diseases 0.000 claims description 21
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims description 18
- 208000002720 Malnutrition Diseases 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 18
- 238000002512 chemotherapy Methods 0.000 claims description 18
- 208000014674 injury Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 210000000813 small intestine Anatomy 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000002496 gastric effect Effects 0.000 claims description 13
- 206010061172 Gastrointestinal injury Diseases 0.000 claims description 12
- 206010022680 Intestinal ischaemia Diseases 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 12
- 208000027418 Wounds and injury Diseases 0.000 claims description 12
- 208000037817 intestinal injury Diseases 0.000 claims description 12
- 235000018343 nutrient deficiency Nutrition 0.000 claims description 12
- 235000020824 obesity Nutrition 0.000 claims description 12
- 230000005855 radiation Effects 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 230000001454 enterotrophic effect Effects 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 206010012735 Diarrhoea Diseases 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 230000001228 trophic effect Effects 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000031729 Bacteremia Diseases 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 6
- 208000015943 Coeliac disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000002633 Febrile Neutropenia Diseases 0.000 claims description 6
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 6
- 206010016946 Food allergy Diseases 0.000 claims description 6
- 208000007882 Gastritis Diseases 0.000 claims description 6
- 206010059028 Gastrointestinal ischaemia Diseases 0.000 claims description 6
- 208000013016 Hypoglycemia Diseases 0.000 claims description 6
- 206010025476 Malabsorption Diseases 0.000 claims description 6
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 6
- 208000004535 Mesenteric Ischemia Diseases 0.000 claims description 6
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 6
- 201000010927 Mucositis Diseases 0.000 claims description 6
- 206010051606 Necrotising colitis Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 206010033654 Pancreatitis necrotising Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 206010049416 Short-bowel syndrome Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000001925 catabolic effect Effects 0.000 claims description 6
- 201000003146 cystitis Diseases 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 235000020932 food allergy Nutrition 0.000 claims description 6
- 230000005176 gastrointestinal motility Effects 0.000 claims description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
- 235000000824 malnutrition Nutrition 0.000 claims description 6
- 230000001071 malnutrition Effects 0.000 claims description 6
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 6
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 6
- 206010034674 peritonitis Diseases 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 208000001162 steatorrhea Diseases 0.000 claims description 6
- 230000007863 steatosis Effects 0.000 claims description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 206010044697 tropical sprue Diseases 0.000 claims description 6
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 claims description 3
- 101500025069 Bos taurus Glucagon-like peptide 2 Proteins 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 3
- 101500028765 Gallus gallus Glucagon-like peptide 2 Proteins 0.000 claims description 3
- 101500026186 Ovis aries Glucagon-like peptide 2 Proteins 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 210000001100 crypt cell Anatomy 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000003886 intestinal anastomosis Effects 0.000 claims description 3
- 230000003871 intestinal function Effects 0.000 claims description 3
- -1 porcine GLP-2 Proteins 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 claims description 3
- 230000008719 thickening Effects 0.000 claims description 3
- 206010067994 Mucosal atrophy Diseases 0.000 claims description 2
- 206010062065 Perforated ulcer Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000008971 epithelial apoptosis Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000003252 repetitive effect Effects 0.000 claims description 2
- 230000001134 intestinotrophic effect Effects 0.000 claims 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 241001137251 Corvidae Species 0.000 claims 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 1
- 230000003185 calcium uptake Effects 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 241000282693 Cercopithecidae Species 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 206010070545 Bacterial translocation Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- 230000007375 bacterial translocation Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 230000019439 energy homeostasis Effects 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004678 mucosal integrity Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 101500028771 Homo sapiens Glucagon-like peptide 2 Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108010029144 Factor IIa Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102100032879 Glucagon-like peptide 2 receptor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 102100029693 Matrix metalloproteinase-20 Human genes 0.000 description 1
- 108090000609 Matrix metalloproteinase-20 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 108090000155 pancreatic elastase II Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161573748P | 2011-09-12 | 2011-09-12 | |
| US61/573,748 | 2011-09-12 | ||
| PCT/US2012/054941 WO2013040093A2 (en) | 2011-09-12 | 2012-09-12 | Glucagon-like peptide-2 compositions and methods of making and using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017137310A Division JP2017186374A (ja) | 2011-09-12 | 2017-07-13 | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526254A JP2014526254A (ja) | 2014-10-06 |
| JP2014526254A5 true JP2014526254A5 (enExample) | 2015-11-05 |
| JP6206972B2 JP6206972B2 (ja) | 2017-10-04 |
Family
ID=47883955
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529994A Active JP6206972B2 (ja) | 2011-09-12 | 2012-09-12 | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
| JP2017137310A Pending JP2017186374A (ja) | 2011-09-12 | 2017-07-13 | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017137310A Pending JP2017186374A (ja) | 2011-09-12 | 2017-07-13 | グルカゴン様ペプチド−２組成物およびその作製法および使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20160137711A1 (enExample) |
| EP (2) | EP3431098A1 (enExample) |
| JP (2) | JP6206972B2 (enExample) |
| KR (1) | KR102007054B1 (enExample) |
| CN (1) | CN103945861B (enExample) |
| AU (2) | AU2012308636B2 (enExample) |
| BR (1) | BR112014005744B1 (enExample) |
| CA (1) | CA2848204C (enExample) |
| DK (1) | DK2755675T3 (enExample) |
| ES (1) | ES2687651T3 (enExample) |
| PT (1) | PT2755675T (enExample) |
| WO (1) | WO2013040093A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496932A (zh) | 2012-02-27 | 2017-12-22 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| CN108524919A (zh) | 2012-05-17 | 2018-09-14 | 延伸生物科学股份有限公司 | 用于改进的药物递送的载体 |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CN105602877B (zh) * | 2016-01-25 | 2019-02-01 | 广州沃德生物技术有限公司 | 一种定点改造的猪源glp-2重组植物乳杆菌及其制备方法和应用 |
| EP3526242A1 (en) | 2016-10-12 | 2019-08-21 | University of Copenhagen | Peptide dual agonists of gipr and glp2r |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| EP4424362A3 (en) | 2017-06-16 | 2024-11-27 | Zealand Pharma A/S | Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| JP7249492B2 (ja) * | 2017-08-22 | 2023-03-31 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用 |
| KR20230007557A (ko) | 2017-09-22 | 2023-01-12 | 카이트 파마 인코포레이티드 | 키메라 폴리펩티드 및 그의 용도 |
| CA3084326A1 (en) | 2017-09-28 | 2019-04-04 | Jaehyuk Choi | Long-acting conjugates of glp-2 derivatives |
| KR102825098B1 (ko) * | 2017-11-06 | 2025-06-26 | 다케다 야쿠힌 고교 가부시키가이샤 | 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디 |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| WO2019126576A1 (en) | 2017-12-21 | 2019-06-27 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
| WO2019143193A1 (ko) * | 2018-01-19 | 2019-07-25 | 주식회사 펩진 | 재조합 폴리펩타이드 생산용 n-말단 융합 파트너 및 이를 이용하여 재조합 폴리 펩타이드를 생산하는방법 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110305223B (zh) | 2019-06-26 | 2022-05-13 | 重庆派金生物科技有限公司 | 重组串联融合蛋白制备目标多肽的方法 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| JP2023545684A (ja) | 2020-09-30 | 2023-10-31 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートおよび使用の方法 |
| CN114213524A (zh) * | 2021-11-08 | 2022-03-22 | 苏州博领干细胞再生医学有限公司 | 用于胰高血糖素样肽-2抗体检测的包被抗原及纯化方法、重组工程菌及培养方法 |
| CA3252113A1 (en) | 2022-03-30 | 2023-10-05 | Beijing Ql Biopharmaceutical Co Ltd | Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use |
| IT202200015204A1 (it) * | 2022-07-20 | 2024-01-20 | Bioinnova S R L S | Microalghe esprimenti glp-2 e usi relativi |
| JP2025534350A (ja) | 2022-09-30 | 2025-10-15 | エクステンド バイオサイエンシズ インコーポレーテッド | 長時間作用型副甲状腺ホルモン |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| AT387234B (de) | 1987-03-05 | 1988-12-27 | Vogelbusch Gmbh | Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| US5789379A (en) * | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
| US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
| US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| US20030228309A1 (en) | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| WO2004085471A2 (en) * | 2003-03-24 | 2004-10-07 | Novo Nordisk A/S | Glp-2 derivatives |
| CN101171262B (zh) | 2005-05-04 | 2012-06-27 | 西兰制药公司 | 胰高血糖素样肽-2(glp-2)类似物 |
| WO2007074010A1 (en) * | 2005-12-24 | 2007-07-05 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| WO2010091122A1 (en) * | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| BR112012004094A2 (pt) * | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
| WO2011084808A2 (en) * | 2009-12-21 | 2011-07-14 | Amunix Operating Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| KR20130115086A (ko) * | 2010-05-17 | 2013-10-21 | 세빅스 인코포레이티드 | 페길화된 c-펩티드 |
-
2012
- 2012-09-12 PT PT12831010T patent/PT2755675T/pt unknown
- 2012-09-12 CA CA2848204A patent/CA2848204C/en active Active
- 2012-09-12 DK DK12831010.9T patent/DK2755675T3/en active
- 2012-09-12 CN CN201280055552.1A patent/CN103945861B/zh active Active
- 2012-09-12 ES ES12831010T patent/ES2687651T3/es active Active
- 2012-09-12 BR BR112014005744-3A patent/BR112014005744B1/pt active IP Right Grant
- 2012-09-12 WO PCT/US2012/054941 patent/WO2013040093A2/en not_active Ceased
- 2012-09-12 EP EP18176085.1A patent/EP3431098A1/en not_active Withdrawn
- 2012-09-12 AU AU2012308636A patent/AU2012308636B2/en active Active
- 2012-09-12 JP JP2014529994A patent/JP6206972B2/ja active Active
- 2012-09-12 KR KR1020147009519A patent/KR102007054B1/ko active Active
- 2012-09-12 US US14/343,111 patent/US20160137711A1/en not_active Abandoned
- 2012-09-12 EP EP12831010.9A patent/EP2755675B1/en active Active
-
2017
- 2017-07-13 JP JP2017137310A patent/JP2017186374A/ja active Pending
- 2017-11-29 AU AU2017268558A patent/AU2017268558A1/en not_active Abandoned
-
2020
- 2020-01-30 US US16/777,125 patent/US20200392195A1/en not_active Abandoned
-
2023
- 2023-06-06 US US18/330,032 patent/US20240067695A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526254A5 (enExample) | ||
| Finan et al. | Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists | |
| EP3241850B1 (en) | Glp and immunoglobulin hybrid fc fused polypeptide and use thereof | |
| KR101794781B1 (ko) | 펩타이드계 ｇｌｐ－２ 작용제 | |
| KR102034607B1 (ko) | 글루카곤 및 glp-1 공-효능제 화합물 | |
| RU2657573C2 (ru) | Применение долгодействующих пептидов glp-1 | |
| JP2025043342A (ja) | 改善されたペプチド製剤 | |
| CN102718858B (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
| CN102292346B (zh) | 肥胖的治疗 | |
| MX2007013431A (es) | Analogos del peptido 2 semejante al glucagon. | |
| JP2015502336A5 (enExample) | ||
| JP2013537879A (ja) | 部位特異的ｐｅｇ修飾エキセンディン−４アナログ及びその使用 | |
| CN116157413A (zh) | 阿普拉鲁肽的制造、配制和给药 | |
| US20220119473A1 (en) | Acylated oxyntomodulin peptide analog | |
| JP2022551233A (ja) | 異なる構造のｇｌｐ－１アナログペプチド修飾二量体およびその調製方法のｉｉ型糖尿病の治療における用途 | |
| CN102643339A (zh) | 一种glp-1类似物、制备方法及其应用 | |
| Youn et al. | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation | |
| CN102552883B (zh) | 一种多肽复合物、药物组合物、其制备方法和应用 | |
| Qi et al. | Effects of PEGylated porcine glucagon-like peptide-2 therapy in weaning piglets challenged with lipopolysaccharide | |
| JP4800194B2 (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 | |
| Wang et al. | Peptide and peptide-based drugs | |
| US10118954B2 (en) | Apelin analogues | |
| KR20240141165A (ko) | 경구 투여를 위한 조성물들 및 방법들 | |
| WO2024206740A1 (en) | Methods and uses for treating nausea and emesis | |
| NZ753010A (en) | Acylated glp-1/glp-2 dual agonists |